DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline non-cystic fibrosis bronchiectasis therapies in various stages of ...

Electromed Inc (ELMD) reports a robust 19% increase in net revenue, driven by strategic growth in home care and hospital ...

At the recent American College of Allergy, Asthma & Immunology (ACAAI) annual meeting, experts discussed the evolving concept ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity ...

He said: “People with lung conditions like asthma, chronic obstructive pulmonary disease (COPD) or bronchiectasis are also ...

Bronchiectasis is a chronic lung disease that develops when the bronchi (airways) are damaged and permanently widen. It is a progressive condition that causes scarring and thickening of the bronchial ...

Reports Q3 revenue $3.0M vs. $1.2M last year. As of September 30, Armata held approximately $17.1M of unrestricted cash and cash equivalents ...

Why do lots of people get chest infections during the winter?

Electromed ( (ELMD) ) has released its Q1 earnings. Here is a breakdown of the information Electromed presented to its investors. Electromed, ...

COLUMBIA, Mo. (KY3) - A new form of diagnostic imaging is changing how doctors see and treat lung conditions like cystic ...

Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.

Explore the serious risks of long COVID and its potential impact on health. Can lingering symptoms from COVID-19 be fatal?